Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 SKY-0515 dose-ranging study in Huntington's disease
2025-522263-14-00Phase 3Authorised
- Sponsor
- Skyhawk Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of SKY-0515 in Huntington disease (HD) (4 arms), sponsored by Skyhawk Therapeutics. Primary endpoint: Change from baseline to Week 72 in composite Unified Huntington's Disease Rating Scale. Planned start Jul 2026; status: authorised.
02
Drugs
SKY-0515
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2025-522263-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522263-14-00.